Martin Chase Marak
A5000431306- Diabetes Management and Research
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Medication Adherence and Compliance
- Inhalation and Respiratory Drug Delivery
- Chronic Disease Management Strategies
- Pharmaceutical Practices and Patient Outcomes
- Intravenous Infusion Technology and Safety
- Heart Failure Treatment and Management
Jaeb Center for Health Research
2022-2025
Texas A&M University
2023
Objective: To evaluate the insulin-only configuration of iLet® bionic pancreas (BP) in youth 6-17 years old with type 1 diabetes (T1D). Research Design and Methods: In this multicenter, randomized, controlled trial, 165 T1D (6-17 old; baseline HbA1c 5.8%-12.2%; 35% using multiple daily injections, 36% an insulin pump without automation, 4% low glucose suspend, 25% a hybrid closed-loop system before study) were randomly assigned 2:1 to use BP (n = 112) aspart or lispro (BP group) control...
To compare postprandial glucose excursions following a bolus with inhaled technosphere insulin (TI) or subcutaneous rapid-acting analog (RAA) insulin.
Objective: To evaluate the insulin-only configuration of iLet® bionic pancreas (BP) using insulin aspart or lispro in adults with type 1 diabetes (T1D). Methods: In this multicenter, randomized, controlled trial, 161 T1D (18-79 years old, baseline HbA1c 5.5%-13.1%, 32% multiple daily injections, 27% a pump without automation, 5% predictive low glucose suspend, and 36% hybrid closed loop system before study) were randomly assigned 2:1 to use BP (N = 107) (BP group) standard-of-care (SC)...
Activation of GPR119 receptors, expressed on enteroendocrine and pancreatic islet cells, augments glucagon counterregulatory responses to hypoglycemia in pre-clinical models. We hypothesized that MBX-2982, a agonist, would augment experimental participants with type 1 diabetes. To assess this, we designed phase 2a double-masked, cross-over trial 18 (20–60 years) Participants were randomized treatment 600 mg MBX-2982 or placebo daily for 14 days two-week washout between treatments....
<p dir="ltr">Activation of GPR119 receptors, expressed on enteroendocrine and pancreatic islet cells, augments glucagon counterregulatory responses to hypoglycemia in pre-clinical models. We hypothesized that MBX-2982, a agonist, would augment experimental participants with type 1 diabetes.<b> </b>To assess this, we designed phase 2a double-masked, cross-over trial 18 (20–60 years) diabetes. Participants were randomized treatment 600 mg MBX-2982 or placebo daily for 14 days...
<p dir="ltr">Activation of GPR119 receptors, expressed on enteroendocrine and pancreatic islet cells, augments glucagon counterregulatory responses to hypoglycemia in pre-clinical models. We hypothesized that MBX-2982, a agonist, would augment experimental participants with type 1 diabetes.<b> </b>To assess this, we designed phase 2a double-masked, cross-over trial 18 (20–60 years) diabetes. Participants were randomized treatment 600 mg MBX-2982 or placebo daily for 14 days...
To evaluate a regimen of inhaled Technosphere insulin (TI) plus degludec in adults with type 1 diabetes, who prestudy were predominately using either an automated delivery (AID) system or multiple daily injections (MDI) continuous glucose monitoring. At 19 sites, diabetes randomly assigned to TI (N = 62) usual care (UC) continuation method 61) for 17 weeks. Prestudy, AID was used by 48% and MDI 45%. Mean ± SD HbA1c 7.57% 0.97% at baseline 7.62% 1.06% weeks the group 7.59% 0.80% 7.54% 0.77%,...
Continuous glucose monitors (CGMs) have transformed the way people with type 1 diabetes can self-monitor levels. Past studies evaluated accuracy of CGMs in clinic-based studies, but few analyzed their real-world settings. The Insulin-Only Bionic Pancreas Trial provided opportunity to assess blinded Dexcom G6 Pro sensor over first 48-60 h wear using a blood meter (BGM) as comparator for 1073 CGM-BGM pairs across 53 participants. mean absolute relative difference (MARD) was 11.0% median period...
<p dir="ltr">Objective: To compare post-prandial glucose excursions following a bolus with inhaled technosphere insulin (TI) or subcutaneous rapid-acting analogue (RAA) insulin. </p><p dir="ltr">Research Design and Methods: A meal challenge was completed by 122 adults type 1 diabetes using multiple daily injections (MDI), non-automated pump, automated delivery (AID) who were randomized to their usual RAA (N=61) TI (N=61). dir="ltr">Results: The primary outcome, the...
<p dir="ltr">Objective: To compare post-prandial glucose excursions following a bolus with inhaled technosphere insulin (TI) or subcutaneous rapid-acting analogue (RAA) insulin. </p><p dir="ltr">Research Design and Methods: A meal challenge was completed by 122 adults type 1 diabetes using multiple daily injections (MDI), non-automated pump, automated delivery (AID) who were randomized to their usual RAA (N=61) TI (N=61). dir="ltr">Results: The primary outcome, the...
Objective:The scientific literature contains an abundance of prediction models for hospital readmissions.However, no review has yet synthesized their predictors across various patient populations.Therefore, our aim was to examine readmissions 13 populations. Study design & setting:An overview systematic reviews combined with a meta-analytical approach.2,504 different were categorized using common ontologies pool and odds ratios frequencies use in within populations.Results: 28 440 primary...
The bionic pancreas (BP) is initialized with body weight only and doses insulin autonomously without carbohydrate counting, instead using qualitative meal announcements. In case of device malfunction, the BP generates continuously updates backup for injection or pump users, including long-acting dose, a four-period basal profile, short-acting doses, glucose correction factor. Following 13-week trial in type 1 diabetes, participants (6-83 years) completed 2-4 days, which they were randomly...